top of page
Recent Posts

Dabrafenib + Trametinib Improve Overall Response Rates in Pediatric Patients with Low-Grade Gliomas

The combination of two targeted therapies, the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib, significantly increased the overall response rate compared to the standard-of-care chemotherapy combination of carboplatin plus vincristine in pediatric patients with BRAF V600 mutation–positive low-grade gliomas.

Read more:


Search By Tags
bottom of page